Alimera Sciences, Inc. (ALIM): Price and Financial Metrics

Alimera Sciences, Inc. (ALIM): $3.71

0.17 (+4.80%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add ALIM to Watchlist
Sign Up

ALIM Price/Volume Stats

Current price $3.71 52-week high $4.38
Prev. close $3.54 52-week low $1.30
Day low $3.60 Volume 20,000
Day high $3.78 Avg. volume 78,767
50-day MA $3.78 Dividend yield N/A
200-day MA $3.32 Market Cap 194.47M

ALIM Stock Price Chart Interactive Chart >

ALIM POWR Grades

  • Growth is the dimension where ALIM ranks best; there it ranks ahead of 99.07% of US stocks.
  • ALIM's strongest trending metric is Quality; it's been moving down over the last 173 days.
  • ALIM ranks lowest in Quality; there it ranks in the 16th percentile.

ALIM Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 7.23 for ALIMERA SCIENCES INC; that's greater than it is for 84.33% of US stocks.
  • With a year-over-year growth in debt of 45.95%, ALIMERA SCIENCES INC's debt growth rate surpasses 86% of about US stocks.
  • Revenue growth over the past 12 months for ALIMERA SCIENCES INC comes in at 26.67%, a number that bests 82.72% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ALIM, based on their financial statements, market capitalization, and price volatility, are CMTL, FMC, ENVA, TWOU, and AGCO.
  • ALIM's SEC filings can be seen here. And to visit ALIMERA SCIENCES INC's official web site, go to www.alimerasciences.com.

ALIM Valuation Summary

  • In comparison to the median Healthcare stock, ALIM's price/earnings ratio is 136.36% lower, now standing at -10.6.
  • Over the past 167 months, ALIM's EV/EBIT ratio has gone down 10.1.

Below are key valuation metrics over time for ALIM.

Stock Date P/S P/B P/E EV/EBIT
ALIM 2023-12-29 3.3 4.6 -10.6 -21.7
ALIM 2023-12-28 3.0 4.2 -9.5 -20.0
ALIM 2023-12-27 2.9 4.1 -9.4 -19.9
ALIM 2023-12-26 2.9 4.1 -9.3 -19.7
ALIM 2023-12-22 3.0 4.1 -9.5 -19.9
ALIM 2023-12-21 2.9 4.0 -9.2 -19.5

ALIM Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -54.15%.
  • Its year over year revenue growth rate is now at 25.71%.
  • Its 3 year price growth rate is now at -71.58%.
Over the past 15 months, ALIM's revenue has gone down $5,105,000.

The table below shows ALIM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 54.059 -14.407 -18.433
2022-06-30 52.614 -15.226 -17.359
2022-03-31 59.713 -6.936 -6.679
2021-12-31 59.029 -3.224 -4.372
2021-09-30 58.844 1.196 -1.243
2021-06-30 59.164 1.78 2.322

ALIM Price Target

For more insight on analysts targets of ALIM, see our ALIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.83 Average Broker Recommendation 1.5 (Moderate Buy)

Alimera Sciences, Inc. (ALIM) Company Bio


Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.


ALIM Latest News Stream


Event/Time News Detail
Loading, please wait...

ALIM Latest Social Stream


Loading social stream, please wait...

View Full ALIM Social Stream

Latest ALIM News From Around the Web

Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.

Alimera Appoints Maggie A. Pax to Its Board of Directors

Maggie A. Pax Maggie A. Pax Appointed to Board of Directors of Alimera Sciences ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. “Maggie’

Yahoo | November 8, 2023

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with di

Yahoo | October 31, 2023

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript October 26, 2023 Alimera Sciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update Conference Call. [Operator […]

Yahoo | October 27, 2023

Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results

Record net revenue and significant decrease in net loss highlight the quarter

Yahoo | October 26, 2023

Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 85.37% and 4.25%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | October 26, 2023

Read More 'ALIM' Stories Here

ALIM Price Returns

1-mo -2.88%
3-mo 10.42%
6-mo N/A
1-year 68.64%
3-year -54.76%
5-year -78.86%
YTD -14.12%
2023 59.41%
2022 -47.17%
2021 21.56%
2020 -44.33%
2019 -29.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!